Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis

American Journal of Human Genetics

Volumn 63, Issue 3, 1998, Pages 727-736

  Evans, D G R ^a   Wallace, A J ^a   Wu, C L ^a   Trueman, L ^c   Ramsden, R T ^b   Strachan, T ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HETERODUPLEX;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MOSAICISM; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC CELL;

EID: 0032231683     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/302004     Document Type: Article

References (24)

1. Biljsma EK, Wallace AJ, Evans DG (1997) Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet 34:934-936
2. Bourn D, Carter SA, Evans DGR, Goodship J, Coakham H, Strachan T (1994) A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet 55:69-73
3. Bourn D, Strachan T (1995) Highly polymorphic dinucleotide repeat at the NF2 gene. Hum Genet 95:712
4. Bunyan DJ, Crolla JA, Collins AL, Robinson DO (1995) Fluorescence in situ hybridisation studies provide evidence for somatic mosaicism in de novo dystrophin gene deletions. Hum Genet 95:43-45
5. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992a) A clinical study of type 2 neurofibromatosis. QJM 84:603-618
6. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, et al (1992b) A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 29:847-852
7. Evans DGR, Trueman L, Wallace A, Collins S, Strachan T (1998) Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 35:450-455
8. Hall JG (1988) Somatic mosaicism: observations related to clinical genetics. Am J Hum Genet 43:355-363
9. Huson SM (1994) Neurofibromatosis 1: a clinical and genetic overview. In: Huson SM, Hughes RAC (eds) The neurofibromatoses: a pathogenetic and clinical overview. Chapman & Hall, London, pp 160-203
10. Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T (1980) Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 30:851-859
11. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, Mautner VF (1996) Identification of NF2 germline mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 98:534-538
12. Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, et al (1995) Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinoma. Cancer 76: 479-489
13. Kovar H, Auinger A, Jug G, Muller T, Pillwein K (1992) p53 mosaicism with an exon 8 germline mutation in the founder of a cancer prone pedigree. Oncogene 7:2169-2173
14. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio M-P, Pulaski K, Trofatter JA, et al (1994) Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 55: 314-320
15. Mérel P, Hoang-Xuan K, Sanson M, Bijlsma E, Rouleau G, Laurent-Puig P, Pulst S, et al (1995) Screening for germline mutations in the NF2 gene. Genes Chromosom Cancer 12: 117-127
16. Moss C, Green SH (1994) What is segmental neurofibromatosis? Br J Dermatol 130:106-110
17. National Institutes of Health Consensus Development Conference (1988) Neurofibromatosis conference statement. Arch Neurol 45:575-578
18. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450-461
19. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, et al (1996) Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 59:529-539
20. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han F-y, Chretien N, Rangaratnam S, et al (1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59:331-342
21. Saito K, Ikeya K, Kondo E, Komine S, Osawa M, Aikawe E, Fukuyama Y (1995) Somatic mosaicism for a DMD gene deletion. Am J Med Genet 56:80-86
22. Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, Sushmita R, et al (1997) Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 61:843-851
23. Thonney F, Munier F, Balmer A, Heon E, Pescia G, Schorderet DF (1996) Rb1 mutation mosaicism in a retinoblastoma family. Am J Hum Genet Suppl 59:A84
24. Weissenbach J, Gyapay G, Dib C, Vignal A, Monssette J, Vaysseix G, Lathrop M (1992) A second generation linkage map of the human genome. Nature 359:794-801